Clinical evaluation of MK-185: a new hypolipidemic drug.
D000081:Acetamides / Q000097:blood / Q000627:therapeutic use; D000328:Adult; D001796:Blood Protein Disorders / Q000188:drug therapy*; D001798:Blood Proteins; D002784:Cholesterol / Q000097:blood; D002849:Chromatography, Gas; D002986:Clinical Trials as Topic; D004586:Electrophoresis; D005260:Female; D005461:Fluorine / Q000097:blood / Q000627:therapeutic use; D006016:Glycolates / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007455:Iodine / Q000097:blood; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011485:Protein Binding; D014280:Triglycerides / Q000097:blood; D014527:Uric Acid / Q000097:blood
D000081:Acetamides; D001798:Blood Proteins; D006016:Glycolates; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D010919:Placebos; D014280:Triglycerides; D014527:Uric Acid; D005461:Fluorine; D007455:Iodine; D002784:Cholesterol